


- 253 -

CLAIMS

1. A compound of the formula:




wherein:

A is an aryl group;

Q¹ is a covalent bond or an aryl leader group;

J is a sulfonamide linkage:



R¹ is a sulfonamido substituent; and,

Q² is an acid leader group;

and wherein:

A, is a C₅₋₂₀aryl group, and is optionally substituted;

the aryl leader group, if present, is:

a C₁₋₇alkylene group;

and is optionally substituted;

the sulfonamido substituent, R¹, is:

hydrogen,

C₁₋₇alkyl,

C₃₋₂₀heterocyclyl, or

C₅₋₂₀aryl;

the acid leader group, Q², is:

phenylene -C₁₋₇alkylene; or

C₁₋₇alkylene-phenylene ;

and is optionally substituted;


and wherein the phenylene linkage is meta;

and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

AMENDED SHEET

- 254 -

2. A compound according to claim 1, wherein the acid leader group, Q^2 , is phenylene- C_{1-7} alkylene, and is optionally substituted.
3. A compound according to claim 1, wherein the acid leader group, Q^2 , has the following formula, wherein R^{Q2} is C_{1-7} alkylene and the phenylene group is optionally substituted with m substituents, R^B , wherein m is an integer from 0 to 4:



4. A compound according to claim 3, wherein R^{Q2} is a saturated C_{1-7} alkylene group.
5. A compound according to claim 3, wherein R^{Q2} is a partially unsaturated C_{1-7} alkylene group.
6. A compound according to claim 3, wherein R^{Q2} is an aliphatic C_{1-7} alkylene group.
7. A compound according to claim 3, wherein R^{Q2} is a linear C_{1-7} alkylene group.
8. A compound according to claim 3, wherein R^{Q2} is a saturated aliphatic C_{1-7} alkylene group.
9. A compound according to claim 3, wherein R^{Q2} is a saturated linear C_{1-7} alkylene group.
10. A compound according to claim 3, wherein R^{Q2} is a partially unsaturated aliphatic C_{1-7} alkylene group.


AMENDED SHEET

- 255 -

11. A compound according to claim 3, wherein R^{Q2} is a partially unsaturated linear C_{1-7} alkylene group.
12. A compound according to claim 3, wherein R^{Q2} is selected from: $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-(CH_2)_5-$, and $-(CH_2)_6-$, $-CH=CH-$, and $-CH=CH-CH=CH-$.
13. A compound according to claim 3, wherein R^{Q2} is cis or trans $-CH=CH-$.
14. A compound according to claim 3, wherein R^{Q2} is cis $-CH=CH-$.
15. A compound according to claim 3, wherein R^{Q2} is trans $-CH=CH-$.

* * *

16. A compound according to any one of claims 1 to 15, wherein the acid leader group, Q^2 , is unsubstituted.
17. A compound according to any one of claims 1 to 15, wherein the acid leader group, Q^2 , is substituted.
18. A compound according to any one of claims 1 to 15, wherein each R^B is independently selected from: fluoro, chloro, methyl, ethyl, isopropyl, t-butyl, trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, methylthio, amino, dimethylamino, diethylamino, morpholino, acetamido, nitro, and phenyl.
19. A compound according to claim 1, wherein the acid leader group, Q^2 , is:



* * *

AMENDED SHEET

- 256 -

20. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group.
21. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a saturated C₁₋₇alkylene group and is optionally substituted.
22. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a partially unsaturated C₂₋₇alkylene group and is optionally substituted.
23. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is an aliphatic C₁₋₇alkylene group and is optionally substituted.
24. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a linear C₁₋₇alkylene group and is optionally substituted.
25. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a saturated aliphatic C₁₋₇alkylene group and is optionally substituted.
26. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a saturated linear C₁₋₇alkylene group and is optionally substituted.
27. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a partially unsaturated aliphatic C₂₋₇alkylene group and is optionally substituted.
28. A compound according to any one of claims 1 to 19, wherein Q¹ is an aryl leader group and is a partially unsaturated linear C₂₋₇alkylene group and is optionally substituted.

AMENDED SHEET

WJW/LP5958467 - PCT Claims filed under Article 34 in Oct 2002 and before examination

- 257 -

* * *

29. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of at least 2 carbon atoms.
30. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of at least 3 carbon atoms.
31. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of from 2 to 7 carbon atoms.
32. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of from 3 to 7 carbon atoms.
33. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of 2 carbon atoms.
34. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of 3 carbon atoms.
35. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of 4 carbon atoms.
36. A compound according to any one of claims 1 to 28, wherein Q¹ is an aryl leader group and has a backbone of 5 carbon atoms.

* * *

37. A compound according to any one of claims 1 to 36, wherein Q¹ is an aryl leader group and is unsubstituted.

AMENDED SHEET

WJW/LP5958467 - PCT Claims filed under Article 34 in Oct 2002 and before examination

- 258 -

38. A compound according to any one of claims 1 to 36, wherein Q^1 is an aryl leader group and is substituted.
39. A compound according to any one of claims 1 to 36, wherein Q^1 is an aryl leader group and is unsubstituted or substituted with one or more groups selected from: halo, hydroxy, ether, C_{5-20} aryl, acyl, amido, and oxo.
40. A compound according to any one of claims 1 to 36, wherein Q^1 is an aryl leader group and is unsubstituted or substituted with one or more groups selected from: -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -OPr, -Ph, and =O.

* * *

41. A compound according to any one of claims 1 to 40, wherein Q^1 is an aryl leader group and is selected from -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -CH=CH-CH=CH-, and C₅cycloalkyl.
42. A compound according to any one of claims 1 to 40, wherein Q^1 is an aryl leader group and is selected from -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH=CH-, and -CH=CH-CH=CH-.

* * *

43. A compound according to any one of claims 1 to 19, wherein Q^1 is a covalent bond.

* * *

44. A compound according to claim 1, wherein:
 Q^1 is an aryl leader group; and
 Q^2 is a phenylene-meta-C₁₋₇alkylene group.

AMENDED SHEET

- 259 -

45. A compound according to claim 1, wherein:
Q¹ is a covalent bond; and
Q² is a phenylene-meta-C₁₋₇alkylene group.
46. A compound according to claim 1, wherein:
Q¹ is a covalent bond or an aryl leader group having a backbone of at least 2 carbon atoms; and
Q² is a phenylene-meta-C₁₋₇alkylene group.
47. A compound according to claim 1, wherein:
Q¹ is an aryl leader group having a backbone of at least 2 carbon atoms; and
Q² is a phenylene-meta-C₁₋₇alkylene group.

* * *

48. A compound according to claim 1, wherein:
Q¹ is an aryl leader group; and
Q² is a phenylene-meta-ethylene group.
49. A compound according to claim 1, wherein:
Q¹ is a covalent bond; and
Q² is a phenylene-meta-ethylene group.
50. A compound according to claim 1, wherein:
Q¹ is a covalent bond or an aryl leader group having a backbone of at least 2 carbon atoms; and
Q² is a phenylene-meta-ethylene group.
51. A compound according to claim 1, wherein:
Q¹ is an aryl leader group having a backbone of at least 2 carbon atoms; and
Q² is a phenylene-meta-ethylene group.

* * *

AMENDED SHEET

- 260 -

52. A compound according to any one of claims 1 to 51, wherein:
A is C₅₋₂₀heteroaryl or C₅₋₂₀carboaryl, and is optionally substituted.
53. A compound according to any one of claims 1 to 51, wherein:
A is a C₅₋₂₀aryl group derived from one of the following:
benzene, pyridine, furan, indole, pyrrole, imidazole, naphthalene, quinoline,
benzimidazole, benzothiofuran, fluorene, acridine, and carbazole.
54. A compound according to any one of claims 1 to 51, wherein:
A is an optionally substituted phenyl group.
55. A compound according to any one of claims 1 to 51, wherein:
A is a phenyl group optionally substituted with one or more of the following
groups:
fluoro, chloro, bromo, iodo, methyl, ethyl, isopropyl, t-butyl, cyano,
trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, trifluoromethoxy,
phenoxy, methylthio, trifluoromethylthio, hydroxymethyl, amino,
dimethylamino, diethylamino, morpholino, amido, acetamido, acetyl, nitro,
sulfonamido, and phenyl.

* * *

56. A compound according to any one of claims 1 to 55, wherein:
the sulfonamido substituent, R¹, is hydrogen, C₁₋₇alkyl, or C₅₋₂₀aryl.
57. A compound according to any one of claims 1 to 55, wherein:
the sulfonamido substituent, R¹, is hydrogen or C₁₋₇alkyl.
58. A compound according to any one of claims 1 to 55, wherein:
the sulfonamido substituent, R¹, is -H, -Me, or -Et.

AMENDED SHEET

- 261 -

59. A compound according to any one of claims 1 to 55, wherein:
the sulfonamido substituent, R¹, is -H.

* * *

- 60. Compound PX105684.
- 61. Compound PX105685.
- 62. Compound PX105844.
- 63. Compound PX106508.
- 64. Compound PX106509.
- 65. Compound PX106510.
- 66. Compound PX106511.
- 67. Compound PX106512.
- 68. Compound PX116238.
- 69. Compound PX117225.
- 70. Compound PX117226.
- 71. Compound PX117227.
- 72. Compound PX117228.
- 73. Compound PX117250.
- 74. Compound PX117445.
- 75. Compound PX117710.
- 76. Compound PX117712.
- 77. Compound PX117713.
- 78. Compound PX117715.
- 79. Compound PX117734.
- 80. Compound PX117735.
- 81. Compound PX117773.
- 82. Compound PX117774.
- 83. Compound PX117775.
- 84. Compound PX117778.
- 85. Compound PX117779.
- 86. Compound PX117782.
- 87. Compound PX117787.

AMENDED SHEET


- 262 -

- 88. Compound PX117788.
- 89. Compound PX117789.
- 90. Compound PX117790.
- 91. Compound PX117791.
- 92. Compound PX117796.
- 93. Compound PX117798.

AMENDED SHEET

- 263 -

94. A compound of the formula:





wherein:

A is an aryl group;

Q¹ is an aryl leader group;

J is a sulfonamide linkage selected from:



R¹ is a sulfonamido substituent; and,

Q² is an acid leader group;

and wherein:

A, is a C₅₋₂₀aryl group, and is optionally substituted;

the aryl leader group, is:

a C₂₋₇alkylene group

having a backbone of at least 2 carbon atoms;

and is optionally substituted;

the sulfonamido substituent, R¹, is:

hydrogen,

C₁₋₇alkyl,

C₃₋₂₀heterocyclyl, or

C₅₋₂₀aryl;

the acid leader group, Q², is:

phenylene -C₁₋₇alkylene; or

C₁₋₇alkylene-phenylene ;

and is optionally substituted;

and wherein the phenylene linkage is meta or para;

and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

AMENDED SHEET

- 264 -

* * *

95. A compound according to claim 94, wherein J is $-S(=O)_2NR^1-$.
96. A compound according to claim 94, wherein J is $-NR^1S(=O)_2-$.

* * *

97. A compound according to any one of claims 94 to 96, wherein Q^1 is a saturated C_{2-7} alkylene group and is optionally substituted.
98. A compound according to any one of claims 94 to 96, wherein Q^1 is a partially unsaturated C_{2-7} alkylene group and is optionally substituted.
99. A compound according to any one of claims 94 to 96, wherein Q^1 is an aliphatic C_{2-7} alkylene group and is optionally substituted.
100. A compound according to any one of claims 94 to 96, wherein Q^1 is a linear C_{2-7} alkylene group and is optionally substituted.
101. A compound according to any one of claims 94 to 96, wherein Q^1 is a saturated aliphatic C_{2-7} alkylene group and is optionally substituted.
102. A compound according to any one of claims 94 to 96, wherein Q^1 is a saturated linear C_{2-7} alkylene group and is optionally substituted.
103. A compound according to any one of claims 94 to 96, wherein Q^1 is a partially unsaturated aliphatic C_{2-7} alkylene group and is optionally substituted.
104. A compound according to any one of claims 94 to 96, wherein Q^1 is a partially unsaturated linear C_{2-7} alkylene group and is optionally substituted.

AMENDED SHEET

WJW/LP5958467 - For Claims filed under Article 34 in Oct 2002 and before examination

- 265 -

* * *

105. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of at least 3 carbon atoms.
106. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of from 2 to 7 carbon atoms.
107. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of from 3 to 7 carbon atoms.
108. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of 2 carbon atoms.
109. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of 3 carbon atoms.
110. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of 4 carbon atoms.
111. A compound according to any one of claims 94 to 104, wherein Q^1 has a backbone of 5 carbon atoms.

* * *

112. A compound according to any one of claims 94 to 111, wherein Q^1 is unsubstituted.
113. A compound according to any one of claims 94 to 111, wherein Q^1 is substituted.

AMENDED SHEET

- 266 -

114. A compound according to any one of claims 94 to 111, wherein Q^1 is unsubstituted or substituted with one or more groups selected from: halo, hydroxy, ether, C_{5-20} aryl, acyl, amido, and oxo.
115. A compound according to any one of claims 94 to 111, wherein Q^1 is unsubstituted or substituted with one or more groups selected from: -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -OPr, -Ph, and =O.

* * *


116. A compound according to any one of claims 94 to 96, wherein Q^1 is selected from $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-CH=CH-CH=CH-$, and C_5 cycloalkyl.
117. A compound according to any one of claims 94 to 96, wherein Q^1 is selected from $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, and $-CH=CH-CH=CH-$.

* * *

118. A compound according to any one of claims 94 to 117, wherein the acid leader group, Q^2 , is phenylene-meta- C_{1-7} alkylene or phenylene-para- C_{1-7} alkylene, and is optionally substituted.

* * *

119. A compound according to any one of claims 94 to 117, wherein the acid leader group, Q^2 , has the following formula, wherein R^{Q2} is C_{1-7} alkylene and the phenylene group is optionally substituted with m substituents, R^B , wherein m is an integer from 0 to 4:



AMENDED SHEET

- 267 -

120. A compound according to claim 119, wherein R^{Q2} is a saturated C_{1-7} alkylene group.
121. A compound according to claim 119, wherein R^{Q2} is a partially unsaturated C_{1-7} alkylene group.
122. A compound according to claim 119, wherein R^{Q2} is an aliphatic C_{1-7} alkylene group.
123. A compound according to claim 119, wherein R^{Q2} is a linear C_{1-7} alkylene group.
124. A compound according to claim 119, wherein R^{Q2} is a saturated aliphatic C_{1-7} alkylene group.
125. A compound according to claim 119, wherein R^{Q2} is a saturated linear C_{1-7} alkylene group.
126. A compound according to claim 119, wherein R^{Q2} is a partially unsaturated aliphatic C_{1-7} alkylene group.
127. A compound according to claim 119, wherein R^{Q2} is a partially unsaturated linear C_{1-7} alkylene group.
128. A compound according to claim 119, wherein R^{Q2} is selected from: $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-(CH_2)_5-$, and $-(CH_2)_6-$, $-CH=CH-$, and $-CH=CH-CH=CH-$.
129. A compound according to claim 119, wherein R^{Q2} is cis or trans $-CH=CH-$.
130. A compound according to claim 119, wherein R^{Q2} is cis $-CH=CH-$.

AMENDED SHEET

WJW/LP5958467 - PCT Claims filed under Article 34 In Oct 2002 and before examination

- 268 -

131. A compound according to claim 119, wherein R^{Q2} is trans -CH=CH-.

* * *

132. A compound according to any one of claims 119 to 131, wherein each R^B is independently selected from: fluoro, chloro, methyl, ethyl, isopropyl, t-butyl, trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, methylthio, amino, dimethylamino, diethylamino, morpholino, acetamido, nitro, and phenyl.


* * *

133. A compound according to any one of claims 94 to 131, wherein the acid leader group, Q^2 , is unsubstituted.

134. A compound according to any one of claims 94 to 131, wherein the acid leader group, Q^2 , is substituted.

* * *

135. A compound according to any one of claims 94 to 117, the acid leader group, Q^2 , is:



* * *

136. A compound according to claim 94, wherein:
J is -S(=O)₂NR¹-; and
 Q^2 is a phenylene-meta-C₁₋₇alkylene group.

137. A compound according to claim 94, wherein:
J is -NR¹S(=O)₂-; and

AMENDED SHEET

- 269 -

Q^2 is a phenylene-meta- C_{1-7} alkylene group.

* * *

138. A compound according to claim 94, wherein:

J is $-S(=O)_2NR^1-$; and

Q^2 a phenylene-meta-ethylene group.

139. A compound according to claim 94, wherein:

J is $-NR^1S(=O)_2-$; and

Q^2 a phenylene-meta-ethylene group.

* * *

140. A compound according to any one of claims 94 to 139, wherein:
A is C_{5-20} heteroaryl or C_{5-20} carboaryl, and is optionally substituted.

141. A compound according to any one of claims 94 to 139, wherein:
A is a C_{5-20} aryl group derived from one of the following:
benzene, pyridine, furan, indole, pyrrole, imidazole, naphthalene, quinoline,
benzimidazole, benzothiofuran, fluorene, acridine, and carbazole.

142. A compound according to any one of claims 94 to 139, wherein:
A is an optionally substituted phenyl group.

143. A compound according to any one of claims 94 to 139, wherein:
A is a phenyl group optionally substituted with one or more of the following
groups:
fluoro, chloro, bromo, iodo, methyl, ethyl, isopropyl, t-butyl, cyano,
trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, trifluoromethoxy,
phenoxy, methylthio, trifluoromethylthio, hydroxymethyl, amino,
dimethylamino, diethylamino, morpholino, amido, acetamido, acetyl, nitro,
sulfonamido, and phenyl.

AMENDED SHEET

- 270 -

* * *

144. A compound according to any one of claims 94 to 143, wherein:
the sulfonamido substituent, R^1 , is hydrogen, C_{1-7} alkyl, or C_{5-20} aryl.
145. A compound according to any one of claims 94 to 143, wherein:
the sulfonamido substituent, R^1 , is hydrogen or C_{1-7} alkyl.
146. A compound according to any one of claims 94 to 143, wherein:
the sulfonamido substituent, R^1 , is -H, -Me, or -Et.
147. A compound according to any one of claims 94 to 143, wherein:
the sulfonamido substituent, R^1 , is -H.


* * *

148. Compound PX106512.
149. Compound PX117446.
150. Compound PX117735.
151. Compound PX117774.
152. Compound PX117779.

AMENDED SHEET

- 271 -

153. A compound of the formula:




wherein:

A is an aryl group;

Q^1 is a covalent bond or an aryl leader group;

J is a sulfonamide linkage:



R^1 is a sulfonamido substituent; and,

Q^2 is an acid leader group;

and wherein:

A, is a C_{5-20} aryl group, and is optionally substituted;

the aryl leader group, if present, is:

a C_{1-7} alkylene group;

and is optionally substituted;

the sulfonamido substituent, R^1 , is:

hydrogen,

C_{1-7} alkyl,

C_{3-20} heterocyclyl, or

C_{5-20} aryl;

the acid leader group, Q^2 , is:

C_{4-7} alkylene

having a backbone length of from 4 to 7 carbon atoms;

and is optionally substituted;

and pharmaceutically acceptable salts, solvates, amides, esters; ethers, chemically protected forms, and prodrugs thereof.

AMENDED SHEET

- 272 -

154. A compound according to claim 153, wherein Q^1 is an aryl leader group.
155. A compound according to claim 153, wherein Q^1 is an aryl leader group and is a saturated C_{1-7} alkylene group and is optionally substituted.
156. A compound according to claim 153, wherein Q^1 is an aryl leader group and is a partially unsaturated C_{2-7} alkylene group and is optionally substituted.
157. A compound according to claim 153, wherein Q^1 is an aryl leader group and is an aliphatic C_{1-7} alkylene group and is optionally substituted.
158. A compound according to claim 153, wherein Q^1 is an aryl leader group and is a linear C_{1-7} alkylene group and is optionally substituted.
159. A compound according to claim 153, wherein Q^1 is an aryl leader group and is a saturated aliphatic C_{1-7} alkylene group and is optionally substituted.
160. A compound according to claim 153, wherein Q^1 is an aryl leader group and is a saturated linear C_{1-7} alkylene group and is optionally substituted.
161. A compound according to claim 153, wherein Q^1 is an aryl leader group and is a partially unsaturated aliphatic C_{2-7} alkylene group and is optionally substituted.
162. A compound according to claim 153, wherein Q^1 is an aryl leader group and is a partially unsaturated linear C_{2-7} alkylene group and is optionally substituted.
- * * *
163. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of at least 2 carbon atoms.

AMENDED SHEET

WJW/LP5958467 - PCT Claims filed under Article 34 in Oct 2002 and before examination

- 273 -

164. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of at least 3 carbon atoms.
165. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of from 2 to 7 carbon atoms.
166. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of from 3 to 7 carbon atoms.
167. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of 2 carbon atoms.
168. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of 3 carbon atoms.
169. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of 4 carbon atoms.
170. A compound according to any one of claims 153 to 162, wherein Q^1 is an aryl leader group and has a backbone of 5 carbon atoms.

* * *

171. A compound according to any one of claims 153 to 170, wherein Q^1 is an aryl leader group and is unsubstituted.
172. A compound according to any one of claims 153 to 170, wherein Q^1 is an aryl leader group and is substituted.
173. A compound according to any one of claims 153 to 170, wherein Q^1 is an aryl leader group and is unsubstituted or substituted with one or more groups selected from: halo, hydroxy, ether, C_{5-20} aryl, acyl, amido, and oxo.

AMENDED SHEET

- 274 -

174. A compound according to any one of claims 153 to 170, wherein Q^1 is an aryl leader group and is unsubstituted or substituted with one or more groups selected from: -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -OPr, -Ph, and =O.

* * *

175. A compound according to claim 153, wherein Q^1 is an aryl leader group and is selected from -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH=CH-, -CH=CH-CH=CH-, and C₅cycloalkyl.

176. A compound according to claim 153, wherein Q^1 is an aryl leader group and is selected from -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH=CH-, and -CH=CH-CH=CH-.

* * *

177. A compound according to claim 153, wherein Q^1 is a covalent bond.

* * *

178. A compound according to any one of claims 153 to 177, wherein the acid leader, Q^2 , is a saturated linear C₄₋₇alkylene group.

* * *

179. A compound according to any one of claims 153 to 178, wherein the acid leader group, Q^2 is substituted.

180. A compound according to any one of claims 153 to 178, wherein the acid leader group, Q^2 is unsubstituted.

* * *

AMENDED SHEET

- 275 -

181. A compound according to any one of claims 153 to 180, wherein:
A is C₅₋₂₀heteroaryl or C₅₋₂₀carboaryl, and is optionally substituted.
182. A compound according to any one of claims 153 to 180, wherein:
A is a C₅₋₂₀aryl group derived from one of the following:
benzene, pyridine, furan, indole, pyrrole, imidazole, naphthalene, quinoline,
benzimidazole, benzothiofuran, fluorene, acridine, and carbazole.
183. A compound according to any one of claims 153 to 180, wherein:
A is an optionally substituted phenyl group.
184. A compound according to any one of claims 153 to 180, wherein:
A is a phenyl group optionally substituted with one or more of the following
groups:
fluoro, chloro, bromo, iodo, methyl, ethyl, isopropyl, t-butyl, cyano,
trifluoromethyl, hydroxy, methoxy, ethoxy, isopropoxy, trifluoromethoxy,
phenoxy, methylthio, trifluoromethylthio, hydroxymethyl, amino,
dimethylamino, diethylamino, morpholino, amido, acetamido, acetyl, nitro,
sulfonamido, and phenyl.

* * *

185. A compound according to any one of claims 153 to 184, wherein:
the sulfonamido substituent, R¹, is hydrogen, C₁₋₇alkyl, or C₅₋₂₀aryl.
186. A compound according to any one of claims 153 to 184, wherein:
the sulfonamido substituent, R¹, is hydrogen or C₁₋₇alkyl.
187. A compound according to any one of claims 153 to 184, wherein:
the sulfonamido substituent, R¹, is -H, -Me, or -Et.
188. A compound according to any one of claims 153 to 184, wherein:
the sulfonamido substituent, R¹, is -H.

AMENDED SHEET

- 276 -

* * *


- 189. Compound PX117233.
- 190. Compound PX117234.
- 191. Compound PX117235.
- 192. Compound PX117236.
- 193. Compound PX117245.
- 194. Compound PX117260.
- 195. Compound PX117410.
- 196. Compound PX117411.
- 197. Compound PX117412.
- 198. Compound PX117414.

AMENDED SHEET

WJW/LP5958467 - PCT Claims filed under Article 34 in Oct 2002 and before examination

- 277 -

199. A compound of the formula:





wherein:

A is an aryl group;

Q^1 is a covalent bond or an aryl leader group;


J is a sulfonamide linkage selected from:



R^1 is a sulfonamido substituent; and,

Q^2 is an acid leader group;

with the proviso that if J is:



then Q^1 is an aryl leader group;

and wherein:

A, is a C_{5-20} aryl group, and is optionally substituted;

the aryl leader group, if present, is a C_{1-7} alkylene group and is optionally substituted;

the sulfonamido substituent, R^1 , is:

hydrogen,

C_{1-7} alkyl,

C_{3-20} heterocyclyl, or

C_{5-20} aryl;

the acid leader group, Q^2 , is:

an ether linkage, $-R^2-X-R^3-$, wherein:

X is -O- or -S-; and;

each R^2 and R^3 is independently a C_{1-7} alkylene group,

and is optionally substituted;

- 278 -

and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

200. A compound according to claim 199, wherein J is $-S(=O)_2NR^1-$.
201. A compound according to claim 199, wherein J is $-NR^1S(=O)_2-$.
202. A compound according to any one of claims 199 to 201, wherein Q^1 is a covalent bond.
203. A compound according to any one of claims 199 to 201, wherein Q^1 is an aryl leader group.
204. A compound according to any one of claims 199 to 201, wherein Q^1 is an aryl leader group and has a backbone of at least 2 carbon atoms.

AMENDED SHEET

- 279 -

* * *

205. A composition comprising a compound according to any one of claims 1 to 209 and a pharmaceutically acceptable carrier or diluent.
206. A compound according to any one of claims 1 to 209 for use in a method of treatment of the human or animal body.
207. A compound according to any one of claims 1 to 209 for use in a method of treatment of a condition mediated by HDAC of the human or animal body.
208. A compound according to any one of claims 1 to 209 for use in a method of treatment of a proliferative condition of the human or animal body.
209. A compound according to any one of claims 1 to 209 for use in a method of treatment of cancer of the human or animal body.
210. A compound according to any one of claims 1 to 209 for use in a method of treatment of psoriasis of the human or animal body.
211. Use of a compound according to any one of claims 1 to 209 for the manufacture of a medicament for use in the treatment of a condition mediated by HDAC.
212. Use of a compound according to any one of claims 1 to 209 for the manufacture of a medicament for use in the treatment of a proliferative condition.
213. Use of a compound according to any one of claims 1 to 209 for the manufacture of a medicament for use in the treatment of cancer.
214. Use of a compound according to any one of claims 1 to 209 for the manufacture of a medicament for use in the treatment of psoriasis.

AMENDED SHEET

- 280 -

215. A method inhibiting HDAC in a cell comprising said cell with an effective amount of a compound according to any one of claims 1 to 209.
216. A method for the treatment of a condition mediated by HDAC comprising administering to a subject suffering from a condition mediated by HDAC a therapeutically-effective amount of a compound according to any one of claims 1 to 209.
217. A method for the treatment of a proliferative condition comprising administering to a subject suffering from a proliferative condition a therapeutically-effective amount of a compound according to any one of claims 1 to 209.
218. A method for the treatment of cancer comprising administering to a subject suffering from cancer a therapeutically-effective amount of a compound according to any one of claims 1 to 209.
219. A method for the treatment of psoriasis comprising administering to a subject suffering from psoriasis a therapeutically-effective amount of a compound according to any one of claims 1 to 209.

* * *